Expertise in
29
conditions

Dr. Jerry R. Mendell

Neurology
Nationwide Children's Hospital
700 Childrens Dr, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
29
conditions
Nationwide Children's Hospital
700 Childrens Dr, 
Columbus, OH 

Overview

Dr. Jerry Mendell, MD is a Neurology Specialist in Columbus, OH and has over 56 years of experience in the medical field. He graduated from University of Texas Southwestern Medical School in 1966.

Dr. Mendell is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, and Spinal Muscular Atrophy (SMA).

He is actively involved in clinical research, co-authoring 217 peer reviewed articles and participating in 20 clinical trials. Dr. Mendell is currently accepting new patients.

Residency

Columbia Presbyterian Medical Center - New York 1969; National Institutes of Health 1970

Specialties

Neurology

Licenses

Psychiatry & Neurology in OH

Hospital Affiliations

Ohio State University Wexner Medical Center
Nationwide Children's Hospital

Languages Spoken

English

Gender

Male

Awards

Distinguished Scholar Award, The Ohio State University, Presented by the President, 2009
Listed, Best Doctors in America
S. Mouchly Small Scientific Achievement Award, The Muscular Dystrophy Association for Significant Contributions to Neuromuscular Disease Research, 2004

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Nationwide Children's Hospital
700 Childrens Dr, Columbus, OH 43205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
Study Phase: Phase 1
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Single-Center, Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 Administered by Systemic Infusion in Subjects With LGMD2E (β-Sarcoglycan Deficiency)
A Single-Center, Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 Administered by Systemic Infusion in Subjects With LGMD2E (β-Sarcoglycan Deficiency)
Enrollment Status: Terminated
Publish Date: January 20, 2026
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Phase I/IIa Gene Transfer Clinical Trial for Variant Late Infantile Neuronal Ceroid Lipofuscinosis, Delivering the CLN6 Gene by Self-Complementary AAV9
Phase I/IIa Gene Transfer Clinical Trial for Variant Late Infantile Neuronal Ceroid Lipofuscinosis, Delivering the CLN6 Gene by Self-Complementary AAV9
Enrollment Status: Completed
Publish Date: October 24, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Genetic
Study Drug: SRP-9001
Study Phase: Phase 1/Phase 2
Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)
Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Genetic
Study Drug: SRP-9001
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

216 Total Publications

Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.
Journal: Cardiology and therapy
Published: April 03, 2026
Similar Doctors
Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
 (3.5 miles away)
614-366-7744
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pierre Giglio is a Neurologist practicing medicine in Columbus, Ohio. Dr. Giglio is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Giglio is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral required
Before you request

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (0.1 miles away)
614-722-4625
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anup Patel is a Neurologist practicing medicine in Columbus, Ohio. Dr. Patel is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Epilepsy, Lennox-Gastaut Syndrome (LGS), West Syndrome, and Seizures. Dr. Patel is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (0.1 miles away)
614-722-4625
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Mytinger is a Neurologist practicing medicine in Columbus, Ohio. Dr. Mytinger is highly rated in 9 conditions, according to our data. His clinical expertise encompasses West Syndrome, Spasmus Nutans, Epilepsy in Children, and Epilepsy. Dr. Mytinger is currently accepting new patients.

Frequently Asked Questions about Dr. Jerry R. Mendell

How do I make an appointment with Dr. Jerry R. Mendell?

You can book an appointment with Dr. Jerry R. Mendell by calling their office at 614-722-2203. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jerry R. Mendell a top-rated expert for Duchenne Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jerry R. Mendell is classified as an Elite expert for Duchenne Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jerry R. Mendell specialize in?

While Dr. Jerry R. Mendell is a Neurology, they have specific expertise in Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Limb-Girdle Muscular Dystrophy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jerry R. Mendell participate in research or clinical trials?

Yes. Dr. Jerry R. Mendell has published 216 articles and abstracts on conditions like Duchenne Muscular Dystrophy. You can view a list of Dr. Jerry R. Mendell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jerry R. Mendell accept my insurance?

Dr. Jerry R. Mendell accepts most major insurance plans, including CareSource and Managed Medicaid. We recommend calling the office directly at 614-722-2203 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mendell's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 14 Advanced Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile